| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3229 | 2017 |
| Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ... New England Journal of Medicine 378 (8), 731-739, 2018 | 2755 | 2018 |
| Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for … DT Cheng, TN Mitchell, A Zehir, RH Shah, R Benayed, A Syed, ... The Journal of molecular diagnostics 17 (3), 251-264, 2015 | 1943 | 2015 |
| Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018 | 775 | 2018 |
| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 630 | 2019 |
| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 585 | 2019 |
| Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ... Clinical Cancer Research 25 (7), 2116-2126, 2019 | 530 | 2019 |
| Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ... Science 364 (6439), 485-491, 2019 | 517 | 2019 |
| NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls JP Solomon, I Linkov, A Rosado, K Mullaney, EY Rosen, D Frosina, ... Modern pathology 33 (1), 38-46, 2020 | 506 | 2020 |
| Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ... Clinical Cancer Research 24 (17), 4154-4161, 2018 | 505 | 2018 |
| Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions JF Hechtman, R Benayed, DM Hyman, A Drilon, A Zehir, D Frosina, ... The American journal of surgical pathology 41 (11), 1547-1551, 2017 | 446 | 2017 |
| A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ... Cancer discovery 7 (9), 963-972, 2017 | 415 | 2017 |
| ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research C Marchiò, M Scaltriti, M Ladanyi, AJ Iafrate, F Bibeau, M Dietel, ... Annals of Oncology 30 (9), 1417-1427, 2019 | 386 | 2019 |
| Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data S Middha, L Zhang, K Nafa, G Jayakumaran, D Wong, HR Kim, ... JCO precision oncology 1, 1-17, 2017 | 360 | 2017 |
| Genetic predictors of response to systemic therapy in esophagogastric cancer YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ... Cancer discovery 8 (1), 49-58, 2018 | 352 | 2018 |
| First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ... The Lancet Oncology 21 (6), 821-831, 2020 | 342 | 2020 |
| What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, ... Annals of Oncology 27 (5), 920-926, 2016 | 319 | 2016 |
| ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ... Nature reviews Clinical oncology 17 (12), 757-770, 2020 | 316 | 2020 |
| Identifying patients with NTRK fusion cancer JP Solomon, R Benayed, JF Hechtman, M Ladanyi Annals of Oncology 30, viii16-viii22, 2019 | 260 | 2019 |
| ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), djx089, 2017 | 256 | 2017 |
David SolitCo-Director, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Centerایمیل تأیید شده در mskcc.org